nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Melphalan—ovarian cancer	0.437	1	CrCtD
L-DOPA—SLC7A5—Melphalan—ovarian cancer	0.225	0.975	CbGbCtD
L-DOPA—Melphalan—Chlorambucil—ovarian cancer	0.188	0.742	CrCrCtD
L-DOPA—L-Tyrosine—Melphalan—ovarian cancer	0.0459	0.181	CrCrCtD
L-DOPA—L-Phenylalanine—Melphalan—ovarian cancer	0.0195	0.0769	CrCrCtD
L-DOPA—CYP2D6—Vinorelbine—ovarian cancer	0.00423	0.0183	CbGbCtD
L-DOPA—CYP2D6—Doxorubicin—ovarian cancer	0.0016	0.00694	CbGbCtD
L-DOPA—PSIP1—myometrium—ovarian cancer	0.00124	0.0497	CbGeAlD
L-DOPA—PSIP1—embryo—ovarian cancer	0.00119	0.0478	CbGeAlD
L-DOPA—PSIP1—Vinblastine—Vinorelbine—ovarian cancer	0.0011	1	CbGdCrCtD
L-DOPA—PSIP1—uterine cervix—ovarian cancer	0.000967	0.0386	CbGeAlD
L-DOPA—PSIP1—decidua—ovarian cancer	0.000921	0.0368	CbGeAlD
L-DOPA—PSIP1—endometrium—ovarian cancer	0.000874	0.035	CbGeAlD
L-DOPA—PSIP1—gonad—ovarian cancer	0.000811	0.0324	CbGeAlD
L-DOPA—PSIP1—uterus—ovarian cancer	0.000806	0.0322	CbGeAlD
L-DOPA—PSIP1—female reproductive system—ovarian cancer	0.000724	0.029	CbGeAlD
L-DOPA—PSIP1—bone marrow—ovarian cancer	0.000684	0.0273	CbGeAlD
L-DOPA—DDC—embryo—ovarian cancer	0.000681	0.0272	CbGeAlD
L-DOPA—PSIP1—female gonad—ovarian cancer	0.000659	0.0263	CbGeAlD
L-DOPA—PSIP1—vagina—ovarian cancer	0.000655	0.0262	CbGeAlD
L-DOPA—SLC7A5—myometrium—ovarian cancer	0.000635	0.0254	CbGeAlD
L-DOPA—SLC7A8—decidua—ovarian cancer	0.000607	0.0243	CbGeAlD
L-DOPA—PSIP1—testis—ovarian cancer	0.000585	0.0234	CbGeAlD
L-DOPA—SLC7A8—gonad—ovarian cancer	0.000535	0.0214	CbGeAlD
L-DOPA—SLC7A5—epithelium—ovarian cancer	0.000498	0.0199	CbGeAlD
L-DOPA—SLC7A5—uterine cervix—ovarian cancer	0.000494	0.0197	CbGeAlD
L-DOPA—DRD4—testis—ovarian cancer	0.000487	0.0195	CbGeAlD
L-DOPA—SLC7A8—female reproductive system—ovarian cancer	0.000477	0.0191	CbGeAlD
L-DOPA—SLC7A5—decidua—ovarian cancer	0.00047	0.0188	CbGeAlD
L-DOPA—SLC7A5—endometrium—ovarian cancer	0.000447	0.0179	CbGeAlD
L-DOPA—SLC7A8—female gonad—ovarian cancer	0.000434	0.0174	CbGeAlD
L-DOPA—SLC7A8—vagina—ovarian cancer	0.000432	0.0173	CbGeAlD
L-DOPA—PSIP1—lymph node—ovarian cancer	0.000424	0.0169	CbGeAlD
L-DOPA—SLC7A5—gonad—ovarian cancer	0.000414	0.0166	CbGeAlD
L-DOPA—SLC15A1—epithelium—ovarian cancer	0.000413	0.0165	CbGeAlD
L-DOPA—DDC—female reproductive system—ovarian cancer	0.000413	0.0165	CbGeAlD
L-DOPA—SLC7A5—uterus—ovarian cancer	0.000412	0.0165	CbGeAlD
L-DOPA—DRD5—female reproductive system—ovarian cancer	0.000397	0.0159	CbGeAlD
L-DOPA—SLC7A8—testis—ovarian cancer	0.000385	0.0154	CbGeAlD
L-DOPA—SLC16A10—epithelium—ovarian cancer	0.000381	0.0152	CbGeAlD
L-DOPA—SLC15A1—endometrium—ovarian cancer	0.000371	0.0148	CbGeAlD
L-DOPA—Isoprenaline—MAPK1—ovarian cancer	0.00037	0.875	CrCbGaD
L-DOPA—SLC7A5—female reproductive system—ovarian cancer	0.00037	0.0148	CbGeAlD
L-DOPA—DRD5—female gonad—ovarian cancer	0.000361	0.0144	CbGeAlD
L-DOPA—SLC7A5—bone marrow—ovarian cancer	0.000349	0.014	CbGeAlD
L-DOPA—SLC7A5—female gonad—ovarian cancer	0.000337	0.0135	CbGeAlD
L-DOPA—SLC7A5—vagina—ovarian cancer	0.000335	0.0134	CbGeAlD
L-DOPA—DDC—testis—ovarian cancer	0.000333	0.0133	CbGeAlD
L-DOPA—SLC16A10—gonad—ovarian cancer	0.000317	0.0127	CbGeAlD
L-DOPA—SLC7A5—testis—ovarian cancer	0.000299	0.0119	CbGeAlD
L-DOPA—SLC16A10—female reproductive system—ovarian cancer	0.000283	0.0113	CbGeAlD
L-DOPA—SLC7A8—lymph node—ovarian cancer	0.000279	0.0112	CbGeAlD
L-DOPA—SLC15A1—vagina—ovarian cancer	0.000278	0.0111	CbGeAlD
L-DOPA—SLC16A10—vagina—ovarian cancer	0.000256	0.0102	CbGeAlD
L-DOPA—DDC—lymph node—ovarian cancer	0.000242	0.00966	CbGeAlD
L-DOPA—SLC16A10—testis—ovarian cancer	0.000229	0.00914	CbGeAlD
L-DOPA—SLC7A5—lymph node—ovarian cancer	0.000216	0.00865	CbGeAlD
L-DOPA—SLC16A10—lymph node—ovarian cancer	0.000166	0.00662	CbGeAlD
L-DOPA—DRD2—testis—ovarian cancer	0.000145	0.00578	CbGeAlD
L-DOPA—CYP2D6—female reproductive system—ovarian cancer	0.000108	0.00431	CbGeAlD
L-DOPA—CYP2D6—female gonad—ovarian cancer	9.8e-05	0.00392	CbGeAlD
L-DOPA—CYP2D6—testis—ovarian cancer	8.7e-05	0.00348	CbGeAlD
L-DOPA—Pain in extremity—Doxorubicin—ovarian cancer	5.44e-05	0.00134	CcSEcCtD
L-DOPA—Diplopia—Doxorubicin—ovarian cancer	5.44e-05	0.00134	CcSEcCtD
L-DOPA—Rash—Melphalan—ovarian cancer	5.42e-05	0.00134	CcSEcCtD
L-DOPA—Dermatitis—Melphalan—ovarian cancer	5.42e-05	0.00133	CcSEcCtD
L-DOPA—Cough—Paclitaxel—ovarian cancer	5.4e-05	0.00133	CcSEcCtD
L-DOPA—Asthenia—Vinorelbine—ovarian cancer	5.39e-05	0.00133	CcSEcCtD
L-DOPA—Arrhythmia—Docetaxel—ovarian cancer	5.38e-05	0.00133	CcSEcCtD
L-DOPA—Orthostatic hypotension—Epirubicin—ovarian cancer	5.37e-05	0.00132	CcSEcCtD
L-DOPA—Convulsion—Paclitaxel—ovarian cancer	5.36e-05	0.00132	CcSEcCtD
L-DOPA—Hypertension—Paclitaxel—ovarian cancer	5.34e-05	0.00132	CcSEcCtD
L-DOPA—Alopecia—Docetaxel—ovarian cancer	5.33e-05	0.00131	CcSEcCtD
L-DOPA—Pruritus—Vinorelbine—ovarian cancer	5.31e-05	0.00131	CcSEcCtD
L-DOPA—Liothyronine—ABCB1—ovarian cancer	5.31e-05	0.125	CrCbGaD
L-DOPA—Mental disorder—Docetaxel—ovarian cancer	5.28e-05	0.0013	CcSEcCtD
L-DOPA—Chest pain—Paclitaxel—ovarian cancer	5.27e-05	0.0013	CcSEcCtD
L-DOPA—Nasopharyngitis—Epirubicin—ovarian cancer	5.26e-05	0.00129	CcSEcCtD
L-DOPA—Anxiety—Paclitaxel—ovarian cancer	5.25e-05	0.00129	CcSEcCtD
L-DOPA—Nausea—Topotecan—ovarian cancer	5.22e-05	0.00129	CcSEcCtD
L-DOPA—Discomfort—Paclitaxel—ovarian cancer	5.21e-05	0.00128	CcSEcCtD
L-DOPA—Gastritis—Epirubicin—ovarian cancer	5.2e-05	0.00128	CcSEcCtD
L-DOPA—Dry mouth—Paclitaxel—ovarian cancer	5.15e-05	0.00127	CcSEcCtD
L-DOPA—Diarrhoea—Vinorelbine—ovarian cancer	5.14e-05	0.00127	CcSEcCtD
L-DOPA—Dysgeusia—Docetaxel—ovarian cancer	5.14e-05	0.00127	CcSEcCtD
L-DOPA—Ataxia—Doxorubicin—ovarian cancer	5.11e-05	0.00126	CcSEcCtD
L-DOPA—Nausea—Melphalan—ovarian cancer	5.11e-05	0.00126	CcSEcCtD
L-DOPA—Confusional state—Paclitaxel—ovarian cancer	5.09e-05	0.00126	CcSEcCtD
L-DOPA—Blood creatinine increased—Doxorubicin—ovarian cancer	5.09e-05	0.00126	CcSEcCtD
L-DOPA—Dysphagia—Epirubicin—ovarian cancer	5.08e-05	0.00125	CcSEcCtD
L-DOPA—Back pain—Docetaxel—ovarian cancer	5.08e-05	0.00125	CcSEcCtD
L-DOPA—Oedema—Paclitaxel—ovarian cancer	5.05e-05	0.00124	CcSEcCtD
L-DOPA—Muscle spasms—Docetaxel—ovarian cancer	5.05e-05	0.00124	CcSEcCtD
L-DOPA—Shock—Paclitaxel—ovarian cancer	4.97e-05	0.00122	CcSEcCtD
L-DOPA—Dizziness—Vinorelbine—ovarian cancer	4.97e-05	0.00122	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—ovarian cancer	4.97e-05	0.00122	CcSEcCtD
L-DOPA—Angina pectoris—Epirubicin—ovarian cancer	4.95e-05	0.00122	CcSEcCtD
L-DOPA—Thrombocytopenia—Paclitaxel—ovarian cancer	4.95e-05	0.00122	CcSEcCtD
L-DOPA—Hyperhidrosis—Paclitaxel—ovarian cancer	4.88e-05	0.0012	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—ovarian cancer	4.86e-05	0.0012	CcSEcCtD
L-DOPA—Anaemia—Docetaxel—ovarian cancer	4.85e-05	0.0012	CcSEcCtD
L-DOPA—Anorexia—Paclitaxel—ovarian cancer	4.82e-05	0.00119	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—ovarian cancer	4.81e-05	0.00119	CcSEcCtD
L-DOPA—Vomiting—Vinorelbine—ovarian cancer	4.78e-05	0.00118	CcSEcCtD
L-DOPA—Rash—Vinorelbine—ovarian cancer	4.74e-05	0.00117	CcSEcCtD
L-DOPA—Dermatitis—Vinorelbine—ovarian cancer	4.73e-05	0.00117	CcSEcCtD
L-DOPA—Hypotension—Paclitaxel—ovarian cancer	4.72e-05	0.00116	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Epirubicin—ovarian cancer	4.72e-05	0.00116	CcSEcCtD
L-DOPA—Headache—Vinorelbine—ovarian cancer	4.71e-05	0.00116	CcSEcCtD
L-DOPA—Syncope—Docetaxel—ovarian cancer	4.71e-05	0.00116	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—ovarian cancer	4.7e-05	0.00116	CcSEcCtD
L-DOPA—Leukopenia—Docetaxel—ovarian cancer	4.7e-05	0.00116	CcSEcCtD
L-DOPA—Pollakiuria—Epirubicin—ovarian cancer	4.69e-05	0.00116	CcSEcCtD
L-DOPA—Palpitations—Docetaxel—ovarian cancer	4.64e-05	0.00114	CcSEcCtD
L-DOPA—Weight increased—Epirubicin—ovarian cancer	4.62e-05	0.00114	CcSEcCtD
L-DOPA—Loss of consciousness—Docetaxel—ovarian cancer	4.61e-05	0.00114	CcSEcCtD
L-DOPA—Weight decreased—Epirubicin—ovarian cancer	4.6e-05	0.00113	CcSEcCtD
L-DOPA—Cough—Docetaxel—ovarian cancer	4.58e-05	0.00113	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—ovarian cancer	4.58e-05	0.00113	CcSEcCtD
L-DOPA—Insomnia—Paclitaxel—ovarian cancer	4.57e-05	0.00113	CcSEcCtD
L-DOPA—Convulsion—Docetaxel—ovarian cancer	4.55e-05	0.00112	CcSEcCtD
L-DOPA—Paraesthesia—Paclitaxel—ovarian cancer	4.54e-05	0.00112	CcSEcCtD
L-DOPA—Hypertension—Docetaxel—ovarian cancer	4.53e-05	0.00112	CcSEcCtD
L-DOPA—Dyspnoea—Paclitaxel—ovarian cancer	4.5e-05	0.00111	CcSEcCtD
L-DOPA—Somnolence—Paclitaxel—ovarian cancer	4.49e-05	0.00111	CcSEcCtD
L-DOPA—Chest pain—Docetaxel—ovarian cancer	4.47e-05	0.0011	CcSEcCtD
L-DOPA—Nausea—Vinorelbine—ovarian cancer	4.46e-05	0.0011	CcSEcCtD
L-DOPA—Dyspepsia—Paclitaxel—ovarian cancer	4.45e-05	0.0011	CcSEcCtD
L-DOPA—Neuropathy peripheral—Epirubicin—ovarian cancer	4.44e-05	0.00109	CcSEcCtD
L-DOPA—Urinary tract infection—Epirubicin—ovarian cancer	4.4e-05	0.00108	CcSEcCtD
L-DOPA—Decreased appetite—Paclitaxel—ovarian cancer	4.39e-05	0.00108	CcSEcCtD
L-DOPA—Dry mouth—Docetaxel—ovarian cancer	4.37e-05	0.00108	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—ovarian cancer	4.37e-05	0.00108	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Paclitaxel—ovarian cancer	4.36e-05	0.00107	CcSEcCtD
L-DOPA—Fatigue—Paclitaxel—ovarian cancer	4.36e-05	0.00107	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—ovarian cancer	4.34e-05	0.00107	CcSEcCtD
L-DOPA—Pain—Paclitaxel—ovarian cancer	4.32e-05	0.00106	CcSEcCtD
L-DOPA—Constipation—Paclitaxel—ovarian cancer	4.32e-05	0.00106	CcSEcCtD
L-DOPA—Confusional state—Docetaxel—ovarian cancer	4.32e-05	0.00106	CcSEcCtD
L-DOPA—Oedema—Docetaxel—ovarian cancer	4.28e-05	0.00106	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—ovarian cancer	4.28e-05	0.00105	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—ovarian cancer	4.25e-05	0.00105	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—ovarian cancer	4.23e-05	0.00104	CcSEcCtD
L-DOPA—Shock—Docetaxel—ovarian cancer	4.21e-05	0.00104	CcSEcCtD
L-DOPA—Thrombocytopenia—Docetaxel—ovarian cancer	4.19e-05	0.00103	CcSEcCtD
L-DOPA—Feeling abnormal—Paclitaxel—ovarian cancer	4.16e-05	0.00103	CcSEcCtD
L-DOPA—Gastrointestinal pain—Paclitaxel—ovarian cancer	4.13e-05	0.00102	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—ovarian cancer	4.11e-05	0.00101	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—ovarian cancer	4.09e-05	0.00101	CcSEcCtD
L-DOPA—Anorexia—Docetaxel—ovarian cancer	4.08e-05	0.00101	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—ovarian cancer	4.08e-05	0.001	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—ovarian cancer	4.07e-05	0.001	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—ovarian cancer	4.07e-05	0.001	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—ovarian cancer	4.05e-05	0.000997	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—ovarian cancer	4.02e-05	0.000989	CcSEcCtD
L-DOPA—Urticaria—Paclitaxel—ovarian cancer	4.01e-05	0.000989	CcSEcCtD
L-DOPA—Hypotension—Docetaxel—ovarian cancer	4e-05	0.000986	CcSEcCtD
L-DOPA—Abdominal pain—Paclitaxel—ovarian cancer	3.99e-05	0.000984	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—ovarian cancer	3.99e-05	0.000982	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—ovarian cancer	3.91e-05	0.000964	CcSEcCtD
L-DOPA—Insomnia—Docetaxel—ovarian cancer	3.87e-05	0.000954	CcSEcCtD
L-DOPA—Paraesthesia—Docetaxel—ovarian cancer	3.85e-05	0.000948	CcSEcCtD
L-DOPA—Dyspnoea—Docetaxel—ovarian cancer	3.82e-05	0.000941	CcSEcCtD
L-DOPA—Somnolence—Docetaxel—ovarian cancer	3.81e-05	0.000938	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—ovarian cancer	3.78e-05	0.000932	CcSEcCtD
L-DOPA—Flushing—Epirubicin—ovarian cancer	3.77e-05	0.00093	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—ovarian cancer	3.77e-05	0.000929	CcSEcCtD
L-DOPA—Dyspepsia—Docetaxel—ovarian cancer	3.77e-05	0.000929	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—ovarian cancer	3.76e-05	0.000927	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—ovarian cancer	3.74e-05	0.000922	CcSEcCtD
L-DOPA—Decreased appetite—Docetaxel—ovarian cancer	3.72e-05	0.000917	CcSEcCtD
L-DOPA—Hypersensitivity—Paclitaxel—ovarian cancer	3.72e-05	0.000917	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—ovarian cancer	3.72e-05	0.000915	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Docetaxel—ovarian cancer	3.7e-05	0.000911	CcSEcCtD
L-DOPA—Fatigue—Docetaxel—ovarian cancer	3.69e-05	0.00091	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—ovarian cancer	3.69e-05	0.000909	CcSEcCtD
L-DOPA—Constipation—Docetaxel—ovarian cancer	3.66e-05	0.000902	CcSEcCtD
L-DOPA—Pain—Docetaxel—ovarian cancer	3.66e-05	0.000902	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—ovarian cancer	3.63e-05	0.000895	CcSEcCtD
L-DOPA—Asthenia—Paclitaxel—ovarian cancer	3.63e-05	0.000893	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—ovarian cancer	3.59e-05	0.000885	CcSEcCtD
L-DOPA—Pruritus—Paclitaxel—ovarian cancer	3.57e-05	0.000881	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—ovarian cancer	3.56e-05	0.000878	CcSEcCtD
L-DOPA—Feeling abnormal—Docetaxel—ovarian cancer	3.53e-05	0.00087	CcSEcCtD
L-DOPA—Gastrointestinal pain—Docetaxel—ovarian cancer	3.5e-05	0.000863	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—ovarian cancer	3.49e-05	0.00086	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—ovarian cancer	3.49e-05	0.000859	CcSEcCtD
L-DOPA—Tension—Epirubicin—ovarian cancer	3.47e-05	0.000856	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—ovarian cancer	3.47e-05	0.000854	CcSEcCtD
L-DOPA—Diarrhoea—Paclitaxel—ovarian cancer	3.46e-05	0.000852	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—ovarian cancer	3.44e-05	0.000847	CcSEcCtD
L-DOPA—Back pain—Epirubicin—ovarian cancer	3.42e-05	0.000844	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—ovarian cancer	3.4e-05	0.000838	CcSEcCtD
L-DOPA—Abdominal pain—Docetaxel—ovarian cancer	3.39e-05	0.000834	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—ovarian cancer	3.36e-05	0.000828	CcSEcCtD
L-DOPA—Dizziness—Paclitaxel—ovarian cancer	3.34e-05	0.000823	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—ovarian cancer	3.34e-05	0.000822	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—ovarian cancer	3.32e-05	0.000819	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—ovarian cancer	3.3e-05	0.000812	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—ovarian cancer	3.28e-05	0.000809	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—ovarian cancer	3.27e-05	0.000806	CcSEcCtD
L-DOPA—Agitation—Epirubicin—ovarian cancer	3.25e-05	0.000801	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—ovarian cancer	3.23e-05	0.000795	CcSEcCtD
L-DOPA—Tension—Doxorubicin—ovarian cancer	3.21e-05	0.000792	CcSEcCtD
L-DOPA—Vomiting—Paclitaxel—ovarian cancer	3.21e-05	0.000792	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—ovarian cancer	3.21e-05	0.00079	CcSEcCtD
L-DOPA—Malaise—Epirubicin—ovarian cancer	3.19e-05	0.000786	CcSEcCtD
L-DOPA—Rash—Paclitaxel—ovarian cancer	3.19e-05	0.000785	CcSEcCtD
L-DOPA—Dermatitis—Paclitaxel—ovarian cancer	3.18e-05	0.000784	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—ovarian cancer	3.18e-05	0.000784	CcSEcCtD
L-DOPA—Syncope—Epirubicin—ovarian cancer	3.17e-05	0.000782	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—ovarian cancer	3.17e-05	0.000781	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—ovarian cancer	3.17e-05	0.000781	CcSEcCtD
L-DOPA—Headache—Paclitaxel—ovarian cancer	3.17e-05	0.00078	CcSEcCtD
L-DOPA—Hypersensitivity—Docetaxel—ovarian cancer	3.16e-05	0.000777	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—ovarian cancer	3.15e-05	0.000776	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—ovarian cancer	3.13e-05	0.000771	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—ovarian cancer	3.11e-05	0.000767	CcSEcCtD
L-DOPA—Cough—Epirubicin—ovarian cancer	3.09e-05	0.000761	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—ovarian cancer	3.09e-05	0.00076	CcSEcCtD
L-DOPA—Asthenia—Docetaxel—ovarian cancer	3.07e-05	0.000757	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—ovarian cancer	3.07e-05	0.000756	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—ovarian cancer	3.06e-05	0.000753	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—ovarian cancer	3.04e-05	0.000749	CcSEcCtD
L-DOPA—Pruritus—Docetaxel—ovarian cancer	3.03e-05	0.000747	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—ovarian cancer	3.03e-05	0.000746	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—ovarian cancer	3.01e-05	0.000742	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—ovarian cancer	3.01e-05	0.000742	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—ovarian cancer	3e-05	0.00074	CcSEcCtD
L-DOPA—Nausea—Paclitaxel—ovarian cancer	3e-05	0.000739	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—ovarian cancer	2.98e-05	0.000734	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—ovarian cancer	2.95e-05	0.000728	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—ovarian cancer	2.95e-05	0.000726	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—ovarian cancer	2.94e-05	0.000724	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—ovarian cancer	2.93e-05	0.000722	CcSEcCtD
L-DOPA—Diarrhoea—Docetaxel—ovarian cancer	2.93e-05	0.000722	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—ovarian cancer	2.91e-05	0.000718	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—ovarian cancer	2.89e-05	0.000713	CcSEcCtD
L-DOPA—Oedema—Epirubicin—ovarian cancer	2.89e-05	0.000712	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—ovarian cancer	2.88e-05	0.000709	CcSEcCtD
L-DOPA—Cough—Doxorubicin—ovarian cancer	2.86e-05	0.000704	CcSEcCtD
L-DOPA—Shock—Epirubicin—ovarian cancer	2.84e-05	0.0007	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—ovarian cancer	2.84e-05	0.000699	CcSEcCtD
L-DOPA—Dizziness—Docetaxel—ovarian cancer	2.83e-05	0.000698	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—ovarian cancer	2.83e-05	0.000697	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—ovarian cancer	2.83e-05	0.000697	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—ovarian cancer	2.79e-05	0.000688	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—ovarian cancer	2.79e-05	0.000687	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—ovarian cancer	2.78e-05	0.000685	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—ovarian cancer	2.75e-05	0.000679	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—ovarian cancer	2.75e-05	0.000678	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—ovarian cancer	2.73e-05	0.000672	CcSEcCtD
L-DOPA—Vomiting—Docetaxel—ovarian cancer	2.72e-05	0.000671	CcSEcCtD
L-DOPA—Rash—Docetaxel—ovarian cancer	2.7e-05	0.000665	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—ovarian cancer	2.7e-05	0.000665	CcSEcCtD
L-DOPA—Dermatitis—Docetaxel—ovarian cancer	2.7e-05	0.000665	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—ovarian cancer	2.69e-05	0.000664	CcSEcCtD
L-DOPA—Headache—Docetaxel—ovarian cancer	2.68e-05	0.000661	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—ovarian cancer	2.67e-05	0.000659	CcSEcCtD
L-DOPA—Shock—Doxorubicin—ovarian cancer	2.63e-05	0.000648	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—ovarian cancer	2.62e-05	0.000645	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—ovarian cancer	2.61e-05	0.000644	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—ovarian cancer	2.59e-05	0.000639	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—ovarian cancer	2.58e-05	0.000637	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—ovarian cancer	2.58e-05	0.000635	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—ovarian cancer	2.57e-05	0.000633	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—ovarian cancer	2.55e-05	0.000628	CcSEcCtD
L-DOPA—Nausea—Docetaxel—ovarian cancer	2.54e-05	0.000627	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—ovarian cancer	2.54e-05	0.000627	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—ovarian cancer	2.51e-05	0.000619	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—ovarian cancer	2.5e-05	0.000615	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—ovarian cancer	2.49e-05	0.000614	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—ovarian cancer	2.49e-05	0.000614	CcSEcCtD
L-DOPA—Pain—Epirubicin—ovarian cancer	2.47e-05	0.000609	CcSEcCtD
L-DOPA—Constipation—Epirubicin—ovarian cancer	2.47e-05	0.000609	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—ovarian cancer	2.42e-05	0.000596	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—ovarian cancer	2.4e-05	0.000591	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—ovarian cancer	2.38e-05	0.000587	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—ovarian cancer	2.38e-05	0.000587	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—ovarian cancer	2.38e-05	0.000585	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—ovarian cancer	2.36e-05	0.000582	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—ovarian cancer	2.35e-05	0.00058	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—ovarian cancer	2.32e-05	0.000572	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—ovarian cancer	2.31e-05	0.000569	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—ovarian cancer	2.3e-05	0.000568	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—ovarian cancer	2.29e-05	0.000565	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—ovarian cancer	2.29e-05	0.000563	CcSEcCtD
L-DOPA—Pain—Doxorubicin—ovarian cancer	2.29e-05	0.000563	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—ovarian cancer	2.28e-05	0.000563	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—ovarian cancer	2.2e-05	0.000543	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—ovarian cancer	2.19e-05	0.000539	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—ovarian cancer	2.13e-05	0.000524	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—ovarian cancer	2.12e-05	0.000523	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—ovarian cancer	2.11e-05	0.000521	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—ovarian cancer	2.07e-05	0.000511	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—ovarian cancer	2.04e-05	0.000504	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—ovarian cancer	1.98e-05	0.000487	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—ovarian cancer	1.97e-05	0.000485	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—ovarian cancer	1.92e-05	0.000473	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—ovarian cancer	1.91e-05	0.000471	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—ovarian cancer	1.89e-05	0.000466	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—ovarian cancer	1.84e-05	0.000453	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—ovarian cancer	1.83e-05	0.000451	CcSEcCtD
L-DOPA—Rash—Epirubicin—ovarian cancer	1.82e-05	0.000449	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—ovarian cancer	1.82e-05	0.000448	CcSEcCtD
L-DOPA—Headache—Epirubicin—ovarian cancer	1.81e-05	0.000446	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—ovarian cancer	1.77e-05	0.000435	CcSEcCtD
L-DOPA—Nausea—Epirubicin—ovarian cancer	1.72e-05	0.000423	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—ovarian cancer	1.7e-05	0.000419	CcSEcCtD
L-DOPA—Rash—Doxorubicin—ovarian cancer	1.69e-05	0.000415	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—ovarian cancer	1.68e-05	0.000415	CcSEcCtD
L-DOPA—Headache—Doxorubicin—ovarian cancer	1.67e-05	0.000413	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—ovarian cancer	1.59e-05	0.000391	CcSEcCtD
L-DOPA—DRD3—Signaling by GPCR—PIK3CD—ovarian cancer	3.42e-06	0.000288	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL2—ovarian cancer	3.39e-06	0.000285	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—MAPK3—ovarian cancer	3.36e-06	0.000282	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CB—ovarian cancer	3.36e-06	0.000282	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CB—ovarian cancer	3.33e-06	0.00028	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CB—ovarian cancer	3.28e-06	0.000276	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CG—ovarian cancer	3.28e-06	0.000276	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PARP1—ovarian cancer	3.24e-06	0.000272	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL8—ovarian cancer	3.23e-06	0.000271	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL8—ovarian cancer	3.2e-06	0.000269	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—MAPK1—ovarian cancer	3.2e-06	0.000269	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—ovarian cancer	3.19e-06	0.000269	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL8—ovarian cancer	3.16e-06	0.000265	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6ST—ovarian cancer	3.1e-06	0.000261	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2—ovarian cancer	3.08e-06	0.000259	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CD—ovarian cancer	3.08e-06	0.000259	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TERT—ovarian cancer	3.07e-06	0.000258	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2—ovarian cancer	3.06e-06	0.000257	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PIK3CA—ovarian cancer	3.05e-06	0.000257	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CB—ovarian cancer	3.02e-06	0.000254	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—ovarian cancer	3.02e-06	0.000254	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2—ovarian cancer	3.02e-06	0.000254	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CB—ovarian cancer	2.98e-06	0.000251	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CG—ovarian cancer	2.98e-06	0.00025	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—ovarian cancer	2.9e-06	0.000244	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CD—ovarian cancer	2.88e-06	0.000242	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—ovarian cancer	2.87e-06	0.000241	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CAV1—ovarian cancer	2.84e-06	0.000239	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—YAP1—ovarian cancer	2.78e-06	0.000234	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2—ovarian cancer	2.78e-06	0.000233	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PIK3CA—ovarian cancer	2.77e-06	0.000233	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TERT—ovarian cancer	2.77e-06	0.000233	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2—ovarian cancer	2.74e-06	0.00023	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ESR1—ovarian cancer	2.74e-06	0.00023	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TERT—ovarian cancer	2.73e-06	0.000229	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB2—ovarian cancer	2.72e-06	0.000229	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6ST—ovarian cancer	2.69e-06	0.000227	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MTOR—ovarian cancer	2.69e-06	0.000226	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CB—ovarian cancer	2.69e-06	0.000226	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PPP2R1A—ovarian cancer	2.63e-06	0.000221	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CD—ovarian cancer	2.62e-06	0.00022	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APC—ovarian cancer	2.59e-06	0.000218	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CG—ovarian cancer	2.59e-06	0.000218	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—NRAS—ovarian cancer	2.59e-06	0.000218	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—ovarian cancer	2.58e-06	0.000217	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRAS—ovarian cancer	2.57e-06	0.000216	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CAV1—ovarian cancer	2.56e-06	0.000215	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CAV1—ovarian cancer	2.52e-06	0.000212	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDKN1B—ovarian cancer	2.52e-06	0.000212	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CB—ovarian cancer	2.51e-06	0.000211	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—ovarian cancer	2.49e-06	0.00021	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CA—ovarian cancer	2.49e-06	0.00021	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK3—ovarian cancer	2.48e-06	0.000208	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—ovarian cancer	2.47e-06	0.000208	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2—ovarian cancer	2.47e-06	0.000208	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ESR1—ovarian cancer	2.46e-06	0.000207	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—ovarian cancer	2.46e-06	0.000206	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ESR1—ovarian cancer	2.43e-06	0.000205	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6ST—ovarian cancer	2.42e-06	0.000204	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—ovarian cancer	2.41e-06	0.000203	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—ovarian cancer	2.41e-06	0.000202	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6ST—ovarian cancer	2.39e-06	0.000201	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CTNNB1—ovarian cancer	2.38e-06	0.0002	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK1—ovarian cancer	2.36e-06	0.000198	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—ovarian cancer	2.36e-06	0.000198	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—ovarian cancer	2.34e-06	0.000196	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CG—ovarian cancer	2.33e-06	0.000196	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APC—ovarian cancer	2.33e-06	0.000196	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—NRAS—ovarian cancer	2.33e-06	0.000196	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—ovarian cancer	2.32e-06	0.000195	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—ovarian cancer	2.31e-06	0.000194	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APC—ovarian cancer	2.3e-06	0.000193	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CG—ovarian cancer	2.3e-06	0.000193	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—NRAS—ovarian cancer	2.3e-06	0.000193	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CB—ovarian cancer	2.28e-06	0.000192	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CD—ovarian cancer	2.28e-06	0.000191	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—FASN—ovarian cancer	2.27e-06	0.000191	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—ovarian cancer	2.27e-06	0.00019	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—ovarian cancer	2.25e-06	0.00019	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.23e-06	0.000188	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK3—ovarian cancer	2.23e-06	0.000188	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—ovarian cancer	2.23e-06	0.000187	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK3—ovarian cancer	2.2e-06	0.000185	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—ovarian cancer	2.19e-06	0.000184	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.16e-06	0.000181	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK1—ovarian cancer	2.12e-06	0.000179	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—ovarian cancer	2.12e-06	0.000179	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—ovarian cancer	2.1e-06	0.000176	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—ovarian cancer	2.1e-06	0.000176	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK1—ovarian cancer	2.09e-06	0.000176	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—ovarian cancer	2.09e-06	0.000176	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—ovarian cancer	2.09e-06	0.000176	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—ovarian cancer	2.08e-06	0.000175	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRAS—ovarian cancer	2.07e-06	0.000174	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1B1—ovarian cancer	2.07e-06	0.000174	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CD—ovarian cancer	2.05e-06	0.000172	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—ovarian cancer	2.05e-06	0.000172	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—ovarian cancer	2.04e-06	0.000171	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—ovarian cancer	2.03e-06	0.000171	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CD—ovarian cancer	2.02e-06	0.00017	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—ovarian cancer	2.01e-06	0.000169	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—ovarian cancer	2.01e-06	0.000169	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—ovarian cancer	2e-06	0.000168	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK3—ovarian cancer	1.98e-06	0.000167	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CB—ovarian cancer	1.98e-06	0.000167	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MTOR—ovarian cancer	1.98e-06	0.000167	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—ovarian cancer	1.98e-06	0.000166	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CAV1—ovarian cancer	1.93e-06	0.000162	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—ovarian cancer	1.93e-06	0.000162	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—ovarian cancer	1.91e-06	0.00016	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—ovarian cancer	1.89e-06	0.000159	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK1—ovarian cancer	1.89e-06	0.000159	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—ovarian cancer	1.89e-06	0.000159	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDKN1B—ovarian cancer	1.86e-06	0.000157	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ESR1—ovarian cancer	1.86e-06	0.000156	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—ovarian cancer	1.84e-06	0.000155	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—ovarian cancer	1.84e-06	0.000155	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.83e-06	0.000154	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6ST—ovarian cancer	1.83e-06	0.000154	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—ovarian cancer	1.82e-06	0.000153	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—ovarian cancer	1.82e-06	0.000153	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—ovarian cancer	1.82e-06	0.000153	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—ovarian cancer	1.81e-06	0.000152	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—ovarian cancer	1.81e-06	0.000152	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CB—ovarian cancer	1.79e-06	0.00015	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MTOR—ovarian cancer	1.79e-06	0.00015	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—ovarian cancer	1.78e-06	0.00015	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—ovarian cancer	1.78e-06	0.00015	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—ovarian cancer	1.78e-06	0.000149	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MTOR—ovarian cancer	1.76e-06	0.000148	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CB—ovarian cancer	1.76e-06	0.000148	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APC—ovarian cancer	1.76e-06	0.000148	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CG—ovarian cancer	1.76e-06	0.000148	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NRAS—ovarian cancer	1.76e-06	0.000148	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CTNNB1—ovarian cancer	1.76e-06	0.000148	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—ovarian cancer	1.72e-06	0.000145	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—ovarian cancer	1.72e-06	0.000144	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—ovarian cancer	1.71e-06	0.000144	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—ovarian cancer	1.7e-06	0.000143	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.7e-06	0.000143	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—ovarian cancer	1.69e-06	0.000142	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK3—ovarian cancer	1.68e-06	0.000142	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—ovarian cancer	1.68e-06	0.000141	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDKN1B—ovarian cancer	1.68e-06	0.000141	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMS—ovarian cancer	1.67e-06	0.000141	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—ovarian cancer	1.67e-06	0.000141	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—ovarian cancer	1.66e-06	0.000139	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDKN1B—ovarian cancer	1.65e-06	0.000139	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—ovarian cancer	1.64e-06	0.000138	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—ovarian cancer	1.64e-06	0.000138	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—ovarian cancer	1.64e-06	0.000138	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—ovarian cancer	1.64e-06	0.000138	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—ovarian cancer	1.63e-06	0.000137	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—ovarian cancer	1.62e-06	0.000136	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—ovarian cancer	1.62e-06	0.000136	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—ovarian cancer	1.61e-06	0.000135	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK1—ovarian cancer	1.6e-06	0.000135	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—ovarian cancer	1.6e-06	0.000135	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—ovarian cancer	1.6e-06	0.000134	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—ovarian cancer	1.58e-06	0.000133	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNB1—ovarian cancer	1.58e-06	0.000133	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—ovarian cancer	1.58e-06	0.000133	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNB1—ovarian cancer	1.56e-06	0.000131	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—ovarian cancer	1.55e-06	0.00013	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—ovarian cancer	1.55e-06	0.00013	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CD—ovarian cancer	1.55e-06	0.00013	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—ovarian cancer	1.54e-06	0.00013	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—ovarian cancer	1.53e-06	0.000129	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—ovarian cancer	1.53e-06	0.000129	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—ovarian cancer	1.53e-06	0.000129	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRAS—ovarian cancer	1.53e-06	0.000129	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—ovarian cancer	1.52e-06	0.000128	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—ovarian cancer	1.52e-06	0.000127	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—ovarian cancer	1.51e-06	0.000127	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—ovarian cancer	1.5e-06	0.000127	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—ovarian cancer	1.48e-06	0.000125	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK3—ovarian cancer	1.46e-06	0.000123	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—ovarian cancer	1.45e-06	0.000122	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—ovarian cancer	1.42e-06	0.00012	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—ovarian cancer	1.39e-06	0.000117	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK1—ovarian cancer	1.39e-06	0.000117	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—ovarian cancer	1.39e-06	0.000117	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—ovarian cancer	1.39e-06	0.000117	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—ovarian cancer	1.38e-06	0.000116	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRAS—ovarian cancer	1.38e-06	0.000116	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—ovarian cancer	1.37e-06	0.000116	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—ovarian cancer	1.37e-06	0.000115	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—ovarian cancer	1.36e-06	0.000114	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRAS—ovarian cancer	1.36e-06	0.000114	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MTOR—ovarian cancer	1.35e-06	0.000113	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CB—ovarian cancer	1.35e-06	0.000113	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAV1—ovarian cancer	1.35e-06	0.000113	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—ovarian cancer	1.34e-06	0.000113	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK3—ovarian cancer	1.32e-06	0.000111	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—ovarian cancer	1.32e-06	0.000111	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK3—ovarian cancer	1.3e-06	0.000109	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—ovarian cancer	1.3e-06	0.000109	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—ovarian cancer	1.29e-06	0.000108	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—ovarian cancer	1.28e-06	0.000108	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—ovarian cancer	1.26e-06	0.000106	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	1.26e-06	0.000106	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK1—ovarian cancer	1.25e-06	0.000105	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—ovarian cancer	1.25e-06	0.000105	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	1.25e-06	0.000105	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—ovarian cancer	1.24e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—ovarian cancer	1.24e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK1—ovarian cancer	1.24e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—ovarian cancer	1.24e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—ovarian cancer	1.23e-06	0.000104	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.23e-06	0.000103	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	1.21e-06	0.000102	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—ovarian cancer	1.21e-06	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	1.19e-06	0.0001	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—ovarian cancer	1.18e-06	9.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—ovarian cancer	1.17e-06	9.85e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—ovarian cancer	1.17e-06	9.83e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—ovarian cancer	1.17e-06	9.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—ovarian cancer	1.16e-06	9.79e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—ovarian cancer	1.14e-06	9.56e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—ovarian cancer	1.12e-06	9.41e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	1.09e-06	9.15e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.08e-06	9.07e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	1.07e-06	9.03e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—ovarian cancer	1.07e-06	9e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—ovarian cancer	1.05e-06	8.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—ovarian cancer	1.05e-06	8.85e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—ovarian cancer	1.04e-06	8.76e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRAS—ovarian cancer	1.04e-06	8.74e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—ovarian cancer	1.04e-06	8.74e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—ovarian cancer	1.01e-06	8.47e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK3—ovarian cancer	9.95e-07	8.37e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—ovarian cancer	9.93e-07	8.35e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—ovarian cancer	9.88e-07	8.3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—ovarian cancer	9.68e-07	8.14e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—ovarian cancer	9.64e-07	8.1e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—ovarian cancer	9.51e-07	8e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK1—ovarian cancer	9.47e-07	7.96e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—ovarian cancer	9.47e-07	7.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CB—ovarian cancer	9.4e-07	7.91e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—ovarian cancer	8.94e-07	7.52e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—ovarian cancer	8.89e-07	7.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—ovarian cancer	8.77e-07	7.38e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	8.22e-07	6.91e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—ovarian cancer	8.13e-07	6.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—ovarian cancer	7.95e-07	6.68e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—ovarian cancer	7.6e-07	6.39e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—ovarian cancer	7.28e-07	6.12e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—ovarian cancer	6.71e-07	5.64e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—ovarian cancer	5.73e-07	4.82e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—ovarian cancer	4.68e-07	3.94e-05	CbGpPWpGaD
